New hope: targeted pill may keep blood cancer in check after transplant
NCT ID NCT03564821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the drug ivosidenib as a maintenance therapy for people with IDH1-mutant blood cancers (like AML) after a stem cell transplant. The goal was to find the safest dose and see if it could help prevent the cancer from coming back. 18 participants took the pill daily, starting at 500 mg, with a lower dose option if needed. The study was completed, and results help guide future research on this approach.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1 MUTATION MYELOID NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Johns Hopkins Cancer Center
Baltimore, Maryland, 21218, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.